Skip to main content

Table 3 Medication in JDM patients total, < 20y and ≥ 20y

From: Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study

Medication Patients (n = 59) Patients < 20 y (n = 28) Patients ≥ 20 y (n = 31) p-values
Prednisolone or DMARD at FU, n 17 (28.8) 13 (46.4) 4 (12.9) 0.004
Prednisolone at FU (yes/no), n 10 (16.9) 7 (12.5) 3 (4.8) 0.13
Methotrexat at FU, n 10 (8.5) 9 (16.1) 1 (1.6) 0.01
Prednisolone during disease course, n 51 (86.4) 26 (92.9) 25 (80.6) 0.17
Methotrexat during disease course, n 30 (50.8) 18 (64.3) 12 (38.7) 0.05
Prednisolone medication time, months 31 (14.0–57.0) 24.5 (13.3–35.0) 48.0 (16.0–85.0) 0.05
Cumulative prednisolone total, g 7.90 (30.00–79.23) 6.14 (0.00–16.23) 9.68 (0.00–79.23) 0.03
Cumulative prednisolone 6 m after diagnosisa, g (n = 58/28/31) 2.76 (0.00–6.65) 2.89 (0.00–6.38) 2.61 (0.00–6.65) 0.60
Cumulative prednisolone 2 y after diagnosis, g 4.81 (0.00–0-16.50) 4.26 (0.00–9.80) 6.75 (0.00–16.49) 0.19
Cumulative prednisolone 6.5 y after diagnosis, g 7.35 (0.00–28.39) 6.14 (0.00–12.64) 9.43 (0.00–28.40) 0.18
Time from last prednisolone dose to FU, months 67.0 (0–162.0) 42.7 (0–67.8) 145.0 (0–253.0) 0.002
  1. FU follow up, a n = 56, values are n (%) and median (range). p-values when comparing JDM <20y and JDM ≥20y